 This is a pilot study of a vaccination regime that is designed to efficiently induce anti-tumor T-cell responses in patients with recurrent WHO grade II glioma. The proposed regime combines subcutaneous injections of glioma-associated antigen GAA-derived cytotoxic T-lymphocyte CTL epitope-peptides with simultaneous intramuscular i.m. administration of poly-ICLC. 